02617.HK
TransThera Sciences (Nanjing) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 10.15
+0.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 35.0M | — | — | 1.2M | 124.0K |
| Cost of Revenue | 4.3M | — | — | — | — |
| Gross Profit | 30.7M | — | — | 1.2M | 124.0K |
| Operating Expenses | |||||
| R&D Expense | 163.6K | 246.8M | 244.0M | 379.0K | 297.3K |
| SG&A Expense | 30.1K | 54.8M | 47.7M | 43.1K | 56.6K |
| General & Admin Expense | 30.1K | 54.8M | 47.7M | 43.0K | 56.3K |
| Selling & Marketing Expense | — | — | — | 102.36 | 233.31 |
| Other Expenses | 299.5M | (1.4M) | (5.1M) | 383.3M | 312.1M |
| Total Operating Expenses | 299.7M | 300.2M | 286.7M | 383.7M | 312.5M |
| Cost and Expenses | 304.0M | 300.2M | 286.7M | 383.9M | 312.5M |
| Operating Income (EBIT) | (396.2M) | (300.2M) | (286.7M) | (390.5M) | (312.3M) |
| Non-Operating | |||||
| Interest Income | 8.9M | 4.9M | 2.2M | 12.2M | 6.1M |
| Interest Expense | 127.1K | 121.0K | 201.0K | 248.5K | 184.9K |
| Net Interest Income | 8.7M | 4.8M | 2.0M | 11.9M | 6.0M |
| Other Non-Op Income/Expense | 6.3M | 4.2M | 12.1M | 39.9M | 60.4M |
| Non-Operating Income (excl Interest) | — | (4.3M) | (12.3M) | — | — |
| EBT (Pre-Tax Income) | (390.0M) | (296.0M) | (274.6M) | (350.6M) | (251.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (268.3M) | (296.0M) | (274.6M) | (344.1M) | (250.0M) |
| Earnings from Cont. Ops | (268.3M) | (296.0M) | (274.6M) | (350.6M) | (251.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (267.3M) | (296.0M) | (274.6M) | (350.6M) | (250.0M) |
| Per Share | |||||
| Basic EPS | (HK$1.02) | (HK$0.76) | (HK$0.69) | (HK$990.00) | (HK$790.00) |
| Diluted EPS | (HK$1.02) | (HK$0.76) | (HK$0.69) | (HK$990.00) | (HK$790.00) |
| Revenue Per Share | HK$0.09 | HK$0.00 | HK$0.00 | HK$3.10 | HK$0.34 |
| Shares | |||||
| Basic Shares Outstanding | 401.5M | 389.7M | 396.9M | 381401 | 360386 |
| Diluted Shares Outstanding | 401.5M | 389.7M | 396.9M | 381401 | 360387 |
| Profitability Metrics | |||||
| EBITDA | (267.6M) | (290.8M) | (268.0M) | (416.8M) | (346.9K) |
| D&A | 4.3M | 5.0M | 6.4M | 4.0M | 6.9K |
| EBIT | (271.9M) | (295.8M) | (274.4M) | (420.8M) | (353.8K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026